Crohn's Disease (CD) Treatment Market to Reach $15.01 Billion by 2029 at 5.1% CAGR

 Tailored for companies operating in or entering the crohn’s disease (cd) treatment sector, this analysis highlights core growth drivers, risks, and innovation trends.

 

 What Is The Expected CAGR For The Crohn’s Disease (CD) Treatment Market Through 2025?
 The crohn’s disease (cd) treatment market size has grown steadily in recent years. It will grow from $11.76 billion in 2024 to $12.32 billion in 2025 at a compound annual growth rate (CAGR) of 4.8%. The growth in the historic period can be attributed to rising prevalence of crohn’s disease, growing awareness of the disease, government initiatives, changing lifestyle.
 
 The crohn’s disease (cd) treatment market size is expected to see strong growth in the next few years. It will grow to $15.01 billion in 2029 at a compound annual growth rate (CAGR) of 5.1%. The growth in the forecast period can be attributed to growing demand for combination therapies, increasing adoption of biologics, investments in research and development on crohn’s disease (cd) treatments. Major trends in the forecast period include development biologic drugs, innovative products, advanced diagnostic tools, biosimilars adoption.
 
 Get your free sample today:
 https://www.thebusinessresearchcompany.com/sample.aspx?id=12902&type=smp
 
 Which Key Factors Will Influence Crohn’s Disease (CD) Treatment Market Growth Over 2025–2034?
 The increasing prevalence of inflammatory bowel diseases is expected to propel the growth of the Crohn’s disease (CD) treatment market going forward. Inflammatory bowel disease (IBD) is a group of chronic inflammatory disorders primarily affecting the gastrointestinal (GI) tract. Crohn’s disease (CD) treatment offers relief from symptoms, reduces inflammation, promotes remission and enhances the overall quality of life for individuals suffering from chronic inflammatory bowel disease. For instance, in September 2023, the United States National Library of Medicine, a US-based medical library, estimated that in Canada, the incidence of inflammatory bowel diseases (IBD) was estimated at 30 per 100,000 person years in 2023, with projections indicating a steady increase of approximately 0.58% per year. As of 2023, the prevalence of IBD in Canada reached about 825 per 100,000, with forecasts suggesting that this could rise to 1.1% of the population by 2035. Therefore, the increasing prevalence of inflammatory bowel diseases drives the Crohn’s disease (CD) treatment market. 
 
 Comprehensive Segment-Wise Insights Into The Crohn’s Disease (CD) Treatment Market
 The crohn’s disease (cd) treatmentmarket covered in this report is segmented — 
 
 1) By Drug Type: Antibiotics; Amino Salicylates; Corticosteroids; Immunomodulators; Other Drug Types
 2) By Route of Administration: Oral; Injectable
 3) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies; Drug Stores
 
 Subsegments:
 1) By Antibiotics: Metronidazole; Ciprofloxacin; Rifaximin
 2) By Amino Salicylates: Mesalamine; Sulfasalazine
 3) By Corticosteroids: Prednisone; Budesonide; Hydrocortisone
 4) By Immunomodulators: Azathioprine; Mercaptopurine; Methotrexate
 5) By Other Drug Types: Biologic Therapies; Janus Kinase Inhibitors; Small Molecules
 
 Key Trends Driving Growth In The Crohn’s Disease (CD) Treatment Market
 Major companies operating in the Crohn’s disease (CD) treatment market are introducing new technologies, such as IBDSENSE, to sustain their position in the market. For instance, in March 2023, The IRR Chemistry Hub, a Scotland-based interdisciplinary hub, developed IBDSENSE. This technology aims to improve inflammatory bowel disease diagnosis and monitoring using non-invasive methods, including Crohn’s disease. The project uses fluorescence-based technology to measure the enzyme activity of Granzyme B (GzmB) in patient biosamples. This technology aims to improve the patient experience and treatment choices.
 
 Analysis Of Key Players In Crohn’s Disease (CD) Treatment Market
 Major companies operating in the crohn’s disease (cd) treatment market are Pfizer Inc., Johnson and Johnson Ltd., Merck and Co. Inc., AbbVie Inc., Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, Abbott Laboratories, GlaxoSmithKline PLC, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen Inc., Boehringer Ingelheim International GmbH, Teva Pharmaceutical Industries Ltd., Mylan N.V., Bausch Health Companies Inc., UCB S.A., Sun Pharmaceutical Industries Ltd., Perrigo Company PLC, Dr. Reddy’s Laboratories Ltd., Aurobindo Pharma Limited, Cipla Limited, Ferring B.V., Hikma Pharmaceuticals PLC, Amneal Pharmaceuticals LLC.
 
 View the full crohn’s disease (cd) treatment market report here:
 https://www.thebusinessresearchcompany.com/report/crohns-disease-cd-treatment-global-market-report
 
 What Are The Key Regional Trends In The Crohn’s Disease (CD) Treatment Market?
 North America was the largest region in the Crohn’s disease (CD) treatment market in 2024. The regions covered in Crohn’s disease (CD) treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
 
 Contact Us:
 
 The Business Research Company 
 
 https://thebusinessresearchcompany.com/ 
 
 Americas +1 310–496–7795
 Asia +44 7882 955267 & +91 8897263534
 Europe +44 7882 955267 
 
 Email: info@tbrc.info 
 
 
 Follow Us On:
 
 LinkedIn: https://in.linkedin.com/company/the-business-research-company